COMPANY INFO
Shoulder Innovations, founded in 2009 by Dr. Steve Gunther and EDF Ventures, is a medical device company specializing in shoulder replacement implant systems. With 56 employees, the company is known for its patented InSet™ Glenoid technology, which aims to reduce implant micro-motion and improve surgical outcomes related to glenoid loosening. Their website is https://shoulderinnovations.com and they operate primarily in the therapeutic devices industry. (pitchbook.com, shoulderinnovations.com)
Shoulder Innovations, Inc. is a medical device company established in 2009, specializing in advanced shoulder replacement implant systems. Operating primarily in the therapeutic devices industry, the company is headquartered in Grand Rapids, Michigan, United States. With its patented InSet™ Glenoid technology, Shoulder Innovations aims to reduce implant micromotion and improve surgical outcomes in shoulder arthroplasty. Founded by Dr. Steve Gunther and EDF Ventures, the company currently has 56 employees and is recognized for its innovative solutions to address glenoid loosening, a significant challenge in shoulder replacement surgeries.
Over its history, Shoulder Innovations funding has enabled the company to raise approximately $117.68 million across 12 funding rounds. This robust fundraising track record includes a mix of seed, venture, equity, and secondary transactions. Key financial milestones center on supporting product development, commercial operations, and the expansion of its unique InSet™ Glenoid implant platform. Notably, the most recent $40 million Series E round in March 2025 brings the company’s total funds raised to a significant level, reflecting confidence from a broad spectrum of prominent investors. The company’s funding strategy has focused on leveraging venture capital to fuel rapid development, broaden commercialization, and respond to growing market demand for more reliable and effective shoulder replacement technologies.
This round of Series E equity financing focuses on advancing the commercialization of the InSet™ Total Shoulder and Reverse Shoulder Arthroplasty Systems. The funds are also earmarked for new product development initiatives and general corporate purposes, fueling the next phase of company growth.
The Series D round was designed to support the accelerated expansion of Shoulder Innovations’ commercial and distribution operations. With increasing demand for its product platform, this round facilitated scaling up market reach and operational capacity.
This Series C equity financing was primarily allocated to product development and to broaden the commercialization of the company's comprehensive platform of shoulder replacement products.
The Series A round provided funding to accelerate new product development and to acquire inventory and assets critical to the growing deployment of InSet™ Glenoid technology.
A leading venture capital firm, USVP has participated as a lead investor in multiple Shoulder Innovations funding rounds, including Series C and E. USVP’s involvement has been central to financing the company’s product development and commercialization initiatives.
As a prominent healthcare venture capital investor, Gilde Healthcare Partners has supported Shoulder Innovations by co-leading its Series D and Series E funding rounds—backing the company’s strategic expansions and commercial efforts.
Lightstone Ventures invests heavily in transformative medical technologies. Their participation in the Series C and D rounds underlines their commitment to supporting Shoulder Innovations’ innovation pipeline.
Focused on life sciences investments, Aperture Venture Partners is a significant backer, playing a key role in the Series D and E rounds to support Shoulder Innovations’ commercialization and growth trajectory.
Gilmartin Capital contributed as an investor in the Series D and E rounds, backing expansion activities, strategic product launches, and market growth.
As a healthcare-focused venture capital fund, Arboretum Ventures joined the Series E round, helping to drive strategic initiatives and spur clinical adoption of Shoulder Innovations' technologies.
Sectoral Asset Management provided investment in the Series E round, financing commercialization and next-generation product development efforts.
This early-stage investor was pivotal during Shoulder Innovations’ initial funding phases, leading investments in the Series A and participating in the Series C round to support foundational growth.
Wakestream Ventures played an active role as an early investor, joining Series A and C rounds, supporting product launches and technological innovation.
Alumni Venture Partners participated in the Series C funding, helping catalyze the expansion of the product portfolio and commercialization.
These organizations contributed to various funding rounds, providing capital that spurred early-stage engineering, commercial expansion, and the scaling of organizational infrastructure.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Shoulder Innovations, Inc. funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.